8-K: Nautilus Biotechnology Holds 2025 Annual Meeting, Elects Class I Directors and Ratifies Auditor

Nautilus Biotechnology, Inc. announced the results of its 2025 annual meeting of stockholders, including the election of two Class I directors and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm.

Summary

• Nautilus Biotechnology, Inc. held its 2025 annual meeting of stockholders on June 20, 2025.
• Out of 126,148,469 shares outstanding as of the April 22, 2025 record date, 99,716,163 shares were represented at the meeting.
• Sujal Patel and Matthew McIlwain were elected as Class I directors, each to serve until the Company's 2028 annual meeting of stockholders.
• The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 99,504,636 votes for.
• Former directors Vijay Pande and Michael Altman did not stand for re-election and resigned from the Board, effective upon the Annual Meeting.
• Matthew McIlwain, previously a Class II director, resigned from that role and was subsequently elected as a Class I director.
• The Board approved decreasing the authorized number of directorships to seven (7), effective upon the Annual Meeting, consisting of two Class I, two Class II, and three Class III directorships.

Sentiment

Score: 6

Explanation: The filing reports routine corporate governance matters, including successful director elections and auditor ratification, indicating normal and expected operational procedures. The board size reduction and director changes were previously disclosed, preventing negative surprises.

Positives

• Successful election of directors ensures continuity of board leadership and strategic direction.
• Ratification of the independent auditor maintains standard corporate governance practices and financial oversight.
• High stockholder participation, with 99,716,163 shares represented, indicates strong engagement and support for the company's governance.

Industry Context

This filing is a standard corporate governance update, common across all publicly traded companies, and does not provide specific industry context for the biotechnology sector beyond routine operational compliance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Confirms the election of directors and ratification of the auditor, ensuring continuity in governance and financial oversight. The reduction in board size was previously disclosed.
• Management/Employees: Provides clarity on board composition and leadership.

Next Steps

• Class I directors Sujal Patel and Matthew McIlwain will serve until the Company's 2028 annual meeting of stockholders.
• PricewaterhouseCoopers LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Nautilus Biotechnology, NAUT, SEC filing, 8-K, annual meeting, stockholders, corporate governance, director election, auditor ratification, board of directors, Class I directors, PricewaterhouseCoopers LLP